AR and prostate carcinoma: In advanced prostate cancer (PCa), the dependency of tumor cells on androgen receptor (AR) signaling has made targeting this pathway a primary focus of drug development, with patients receiving androgen deprivation therapy (ADT) as first line treatment for recurrent disease.